Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBIT (2016 - 2025)

Historic EBIT for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$18.4 million.

  • Enanta Pharmaceuticals' EBIT rose 3841.36% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.3 million, marking a year-over-year increase of 2986.42%. This contributed to the annual value of -$85.3 million for FY2025, which is 2986.42% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' EBIT is -$18.4 million, which was up 3841.36% from -$18.9 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' EBIT registered a high of -$18.4 million during Q3 2025, and its lowest value of -$39.5 million during Q1 2023.
  • For the 5-year period, Enanta Pharmaceuticals' EBIT averaged around -$29.8 million, with its median value being -$30.4 million (2021).
  • Per our database at Business Quant, Enanta Pharmaceuticals' EBIT plummeted by 15010.53% in 2021 and then surged by 3841.36% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' EBIT (Quarter) stood at -$30.4 million in 2021, then rose by 1.3% to -$30.0 million in 2022, then dropped by 16.24% to -$34.9 million in 2023, then surged by 32.51% to -$23.5 million in 2024, then rose by 21.9% to -$18.4 million in 2025.
  • Its EBIT stands at -$18.4 million for Q3 2025, versus -$18.9 million for Q2 2025 and -$24.5 million for Q1 2025.